Skip to main content
IWY357
Legend
Product vision
Uncomplicated malaria treatment and resistance management
MoA
Novel and unknown
Key features
No cross-resistance
No resistant mutants identified
Low predicted dose (<100 mg) and long predicted half-life in human
Fast killing
in vitro
and
in vivo
Challenges
Partner drug selection
Status
Good Laboratory Practice (GLP) toxicology studies ongoing
Salt screen underway to develop final form
Next milestone
Completion of Good Laboratory Practice (GLP) toxicology programme
MMV Project Director
Dr Andrew Slade